[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
May 2016

Cerebrospinal Biomarkers in Alzheimer Disease—Potential Roles as Markers of Prognosis and Neuroplasticity

Author Affiliations
  • 1McKnight Brain Institute, Department of Neurology, University of Florida, Gainesville
  • 2Center for Translational Research in Neurodegenerative Diseases, Department of Neuroscience, University of Florida, Gainesville
JAMA Neurol. 2016;73(5):508-510. doi:10.1001/jamaneurol.2016.0090

Biomarkers as aids to diagnosis, prognosis, and effective therapies have become holy grails of translational neuroscience. In neurodegenerative disorders, especially Alzheimer disease (AD), imaging and cerebrospinal fluid (CSF) biomarkers for the amyloid-β (Aβ) protein and tau have found their place in research and clinical trials, enabling much more accurate diagnosis. Despite these advances in diagnostic biomarkers, less progress has been made with respect to biomarkers of progression. Alzheimer disease progresses slowly and has a long preclinical stage prior to clinical manifestations; biomarkers of progression could provide invaluable information to assess the efficacy of potential disease-modifying agents in clinical trials. If medicines modify disease progression by slowing neurodegeneration in the brain, the neurodegeneration biomarker should also be modified.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×